Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
CONCLUSION: Consistent findings across weighting and matching methods suggest PP6M efficacy in reducing and delaying relapses and long-term symptom control compared to PP1M/PP3M in usual-care settings. Additional confounds, such as greater illness severity and more frequent comorbidities and comedications in the ECA, were not fully controlled by the applied statistical methods. Future real-world studies directly comparing PP6M with PP3M/PP1M and adjusting for these confounders are warranted.PMID:37786804 | PMC:PMC10541743 | DOI:10.1177/20451253231200258 (Source: Adv Data)
Source: Adv Data - October 3, 2023 Category: Epidemiology Authors: Ibrahim Turkoz Joshua Wong Benjamin Chee Uzma Siddiqui R Karl Knight Ute Richarz Christoph U Correll Source Type: research
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
CONCLUSION: Consistent findings across weighting and matching methods suggest PP6M efficacy in reducing and delaying relapses and long-term symptom control compared to PP1M/PP3M in usual-care settings. Additional confounds, such as greater illness severity and more frequent comorbidities and comedications in the ECA, were not fully controlled by the applied statistical methods. Future real-world studies directly comparing PP6M with PP3M/PP1M and adjusting for these confounders are warranted.PMID:37786804 | PMC:PMC10541743 | DOI:10.1177/20451253231200258 (Source: Adv Data)
Source: Adv Data - October 3, 2023 Category: Epidemiology Authors: Ibrahim Turkoz Joshua Wong Benjamin Chee Uzma Siddiqui R Karl Knight Ute Richarz Christoph U Correll Source Type: research
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis
Conclusions: This post hoc analysis suggests that PP provides significant benefit in reducing TF or relapse compared with OAPs regardless of duration of illness and highlights the potential benefit of implementing PP earlier in the course of schizophrenia.Trial Registration: ClinicalTrials.gov identifiers NCT01157351 (PRIDE), NCT01081769 (PROSIPAL), and NCT02431702 (DREaM).PMID:37756123 | DOI:10.4088/JCP.23m14788 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - September 27, 2023 Category: Psychiatry Authors: Oliver J Lopena Larry D Alphs Martha Sajatovic Ibrahim Turkoz Liping Sun Karen L Johnston Jennifer K Sliwa Dean M Najarian H Lynn Starr Source Type: research
Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting
CONCLUSION: PP3M initiation was associated with an overall HRU reduction. Subjects switched to PP3M had similar HRU when compared to those who did not, suggesting similar clinical conditions in both groups.PMID:37750003 | DOI:10.1080/14737175.2023.2263650 (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - September 26, 2023 Category: Neurology Authors: Giovanna Cirnigliaro Vera Battini Rita Cafaro Giulia Mosini Simone Vanzetto Tiziano Prodi Monica Macellaro Rodolfo Leuzzi Dario Conti Carla Carnovale Bernardo Dell'Osso Source Type: research
